PKAα cat Inhibitors

Common PKAα cat Inhibitors include, but are not limited to H-89 dihydrochloride CAS 130964-39-5, KT 5720 CAS 108068-98-0, Rp-cAMPS CAS 151837-09-1, PKI (5-24), PKA Inhibitor CAS 99534-03-9 and PKI (14-22) amide (myristoylated) CAS 201422-03-9.

Protein Kinase A (PKA) is a key enzyme that plays a fundamental role in the cyclic AMP (cAMP) signaling pathway, regulating a plethora of cellular processes. PKA is a tetramer consisting of two regulatory subunits and two catalytic subunits. Upon an increase in intracellular cAMP levels, the cAMP molecules bind to the regulatory subunits of PKA, leading to the release and activation of the catalytic subunits. Once released, the catalytic subunits can then phosphorylate a multitude of target proteins, modulating their activity. Among the catalytic subunits, the alpha catalytic subunit (PKAα cat) is of particular interest due to its widespread expression and critical role in various cellular events.

PKAα cat inhibitors are specialized chemical compounds developed to specifically target and inhibit the activity of the PKAα catalytic subunit. These inhibitors function by binding directly to the catalytic pocket or other essential regions of the PKAα cat, thereby blocking its ability to phosphorylate target substrates. By doing so, these inhibitors can modulate the downstream effects mediated by PKAα cat activation. Some PKAα cat inhibitors might employ an ATP-competitive mechanism, wherein they compete with ATP for binding to the kinase's active site. Others might be allosteric in nature, binding to a site distinct from the active site and inducing conformational changes that render the kinase inactive.